Keywords : Oral Cancer, cancer
This report provides data on the therapeutic development for Oral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer . 'Oral Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presen...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Oral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer . 'Oral Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Oral Cancer .
- A review of the Oral Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oral Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Oral Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oral Cancer pipeline depth and focus of Oral Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Oral Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oral Cancer 9
Oral Cancer Therapeutics under Development by Firms 11
Oral Cancer Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Oral Cancer Therapeutics – Products under Development by Firms 18
Oral Cancer Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Oral Cancer Therapeutics Development 20
CEL-SCI Corporation 20
NexMed, Inc. 21
Oral Cancer – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
HPPH - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Tarceva - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Avandia - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Advexin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Actos - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Fludarabine + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Survivin-Derived Peptide Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
PF-00299804 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Filgrastim + Palifermin + Cyclophosphamide + Etoposide + Ifosfamide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Lapatinib Ditosylate + Capecitabine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Taxotere + Cisplatin + 5-FU - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
Erbitux + Radiation Therapy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Curcumin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Docetaxel + Nedaplatin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VTX-2337 + Cetuximab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Multikine + Cisplatin + Radiation Therapy - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Paclitaxel - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZD6474 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oral Cancer Therapeutics – Drug Profile Updates 66
Oral Cancer Therapeutics – Discontinued Products 67
Oral Cancer Therapeutics - Dormant Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70
List of Tables
Number of Products Under Development for Oral Cancer, H1 2012 9
Products under Development for Oral Cancer – Comparative Analysis, H1 2012 10
Number of Products under Development by Firms, H1 2012 11
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 17
Products under Development by Firms, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
CEL-SCI Corporation, H1 2012 20
NexMed, Inc., H1 2012 21
Assessment by Monotherapy Products, H1 2012 22
Assessment by Combination Products, H1 2012 23
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Stage and Molecule Type, H1 2012 27
Oral Cancer Therapeutics – Drug Profile Updates 66
Oral Cancer Therapeutics – Discontinued Products 67
Oral Cancer Therapeutics – Dormant Products 68
List of Figures
Number of Products under Development for Oral Cancer, H1 2012 9
Products under Development for Oral Cancer – Comparative Analysis, H1 2012 10
Products under Development by Firms, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 12
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Pre-Clinical Stage Products, H1 2012 17
Assessment by Monotherapy Products, H1 2012 22
Assessment by Combination Products, H1 2012 23
Assessment by Route of Administration, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Molecule Type, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 27
